Eli Lilly: requests revocation of EUA by FDA
(CercleFinance.com) - Eli Lilly has announced that it has asked the US FDA to revoke the emergency use authorization (EUA) for bamlanivimab (LY-CoV555) 700 mg alone, saying that this request is not due to any new safety concern.
The company explains that this is the final step in the transition to providing only bamlanivimab and etesevimab for administration together in the US for the treatment of Covid-19.
"All sites in the U.S. now have access to obtain doses of etesevimab for administration with bamlanivimab—which together neutralize more of the emerging COVID-19 variants in the U.S. than bamlanivimab alone," the Indianapolis-based group continued.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
The company explains that this is the final step in the transition to providing only bamlanivimab and etesevimab for administration together in the US for the treatment of Covid-19.
"All sites in the U.S. now have access to obtain doses of etesevimab for administration with bamlanivimab—which together neutralize more of the emerging COVID-19 variants in the U.S. than bamlanivimab alone," the Indianapolis-based group continued.
Copyright (c) 2021 CercleFinance.com. All rights reserved.